MONTREAL, QUEBEC--(Marketwire - June 10, 2008) - Ambrilia Biopharma (TSX: AMB) today announced that it will present in vitro and in vivo data on its new HIV integrase inhibitors, a result of a recent lead optimization effort, showing their improved activities against the HIV integrase enzyme and viruses. These data will be presented in a poster entitled "Small Molecule Inhibitors of HIV-1 Integrase" during a poster session on Wednesday, June 11, at the XVII International HIV Drug Resistance Workshop held this week, in Sitges, Spain (June 10-14).
